Image

Electronic Symptom Monitoring Program for Triggered Palliative Referrals in Patients With Thoracic Cancer

Recruiting
18 years of age
Both
Phase N/A

Powered by AI

Overview

This clinical trial evaluates earlier symptom management through remote electronic symptom monitoring (such as through an app on patient's phone), and accessibility of palliative care self-referral by patients with thoracic cancer and caregivers by proxy (legal representative). Thoracic cancer occurs in the chest and often causes symptoms for patients. Patients and/or their caregivers are often unable to attend in-person clinic visits for various reasons. The most frequently reported symptom by patients at initial palliative care consultations is pain, and caregivers' most common concerns are pain management for the patient, stress reduction, and fears about patient decline. Earlier palliative care referral can help control these symptoms before they worsen, providing a better quality of life for patients and caregivers. improve physical and emotional functioning for patients and caregivers in cancer care. This study may help researchers learn how an electronic symptom monitoring program may provide an earlier and more accessible way for patients with thoracic cancer to receive palliative care.

Description

PRIMARY OBJECTIVE:

I. Develop and assess feasibility of a remote electronic symptom monitoring program with a prompted option for palliative care self-referral for patients or caregivers by proxy after diagnosis of a thoracic malignancy.

SECONDARY OBJECTIVE:

I. Evaluate palliative care referral patterns after implementation of a remote electronic symptom monitoring program.

OUTLINE

Patients and their caregivers use the electronic symptom monitoring program to log symptoms once a week (QW) for 24 weeks. Patients and their caregivers also watch a video and review education materials prior to starting the remote symptom monitoring program.

After completion of study intervention, participants are followed up to 2 years.

Eligibility

Inclusion Criteria:

  • PATIENTS: Age ≥ 18 years
  • PATIENTS: Diagnosed with any stage (1-4) or type (non-small cell lung cancer, small cell lung cancer, mesothelioma, thymic carcinoma) of thoracic malignancy
  • PATIENTS: ≥ 2 visits at the Ohio State University Comprehensive Cancer Center (OSUCCC) Thoracic Oncology Clinic
  • PATIENTS: Study enrollment within 12 weeks of initial Thoracic Medical Oncology appointment
  • PATIENTS: Ability to understand and willingness to sign an informed consent document (or indicate approval or disapproval by another means)
  • PATIENTS: Ability to read and understand English
  • PATIENTS: Access to a device with email or text messaging capability
  • CAREGIVERS: Age ≥ 18 years
  • CAREGIVERS: Identified by patient participant as primary caregiver
  • CAREGIVERS: Corresponding patient participant has consented to participate in the study
  • CAREGIVERS: Ability to understand and willingness to sign an informed consent document (or indicate approval or disapproval by another means)
  • CAREGIVERS: Ability to read and understand English
  • CAREGIVERS: Access to a device with email or text messaging capability

Exclusion Criteria:

  • PATIENTS: Patients who have been previously referred to ambulatory palliative care are excluded from participation
  • PATIENTS: Prisoners are excluded from participation
  • PATIENTS: Pregnant patients are excluded from participation
  • PATIENTS: Patients who lack capacity for medical decision-making as determined by their primary oncologist are excluded from participation
  • PATIENTS: There is NO exclusion criteria pertaining to Eastern Cooperative Oncology Group (ECOG) performance status, laboratory values, prior cancer diagnoses, presence of comorbidities or brain metastases

Study details

Malignant Thoracic Neoplasm

NCT06396598

Ohio State University Comprehensive Cancer Center

15 May 2024

Step 1 Get in touch with the nearest study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

FAQs

Learn more about clinical trials

What is a clinical trial?

A clinical trial is a study designed to test specific interventions or treatments' effectiveness and safety, paving the way for new, innovative healthcare solutions.

Why should I take part in a clinical trial?

Participating in a clinical trial provides early access to potentially effective treatments and directly contributes to the healthcare advancements that benefit us all.

How long does a clinical trial take place?

The duration of clinical trials varies. Some trials last weeks, some years, depending on the phase and intention of the trial.

Do I get compensated for taking part in clinical trials?

Compensation varies per trial. Some offer payment or reimbursement for time and travel, while others may not.

How safe are clinical trials?

Clinical trials follow strict ethical guidelines and protocols to safeguard participants' health. They are closely monitored and safety reviewed regularly.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.